Drug Profile

AG 80308

Alternative Names: AG-80308; AGN 232411; AGN-411

Latest Information Update: 28 May 2024

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Allergan
Developer AbbVie; Allgenesis Biotherapeutics
Class Anti-inflammatories; Eye disorder therapies; Peptides
Mechanism of Action Formyl peptide receptor agonists

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

Preclinical Ocular inflammation
No development reported Dry eyes

Most Recent Events

28 May 2024 No recent reports of development identified for phase-I development in Dry-eyes in USA (Ophthalmic, Liquid)
19 Jun 2023 Efficacy and adverse events data from a phase Ib trial in Dry eyes released by Allgenesis Biotherapeutics
19 Jun 2023 Allgenesis Biotherapeutics plans a phase II trial for Dry eyes in the first quarter of 2024

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com